59804-37-4 Usage
Description
Tenoxicam is a non-steroidal antiinflammatory agent with a profile similar to related
piroxicam and now withdrawn isoxicam (55). It is useful in the treatment of rheumatoid
arthritis, osteoarthritis and related disorders.
Chemical Properties
Yellow Crystalline Powder
Uses
Different sources of media describe the Uses of 59804-37-4 differently. You can refer to the following data:
1. Tenoxicam has been used:as a non-steroidal anti-inflammatory agent (NSAID) to study its effects on root gravitropism in Arabidopsis thalianaas a standard in microanalysis of NSAIDs by spectrophotometryto test its effect on surface potential andmembrane fluidity modification in phosphoglyceride monolayers
2. antipsychotic
3. Nonsteroidal anti-inflamatory agent
Definition
ChEBI: A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatm
nt of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for short term treatment of acute musculoskeletal disorders including strains, sprains and other soft-tissue injuries.
Brand name
Tilcotil
Biochem/physiol Actions
Tenoxicam (TX) possesses antipyretic?and analgesic effects. It elicits radical scavenging activity and has the potential to treat enkylosing spondylitis, extra-articular diseases, acute gout, and rheumatic diseases. It is also effective in treating primary dysmenorrhea, postpartum uterine contraction pain, and post-operation backaches. TX is capable of inhibiting prostaglandin synthesis.
Clinical Use
NSAID and analgesic
Drug interactions
Potentially hazardous interactions with other drugs
ACE inhibitors and angiotensin-II antagonists:
antagonism of hypotensive effect; increased risk of
nephrotoxicity and hyperkalaemia.
Analgesics: avoid concomitant use of 2 or more
NSAIDs, including aspirin (increased side effects);
avoid with ketorolac (increased risk of side effects
and haemorrhage).
Antibacterials: possibly increased risk of convulsions
with quinolones.
Anticoagulants: effects of coumarins and
phenindione enhanced; possibly increased risk of
bleeding with heparins, dabigatran and edoxaban -
avoid long term use with edoxaban.
Antidepressants: increased risk of bleeding with
SSRIs and venlaflaxine.
Antidiabetic agents: effects of sulphonylureas
enhanced.
Antiepileptics: possibly increased phenytoin
concentration.
Antivirals: increased risk of haematological toxicity
with zidovudine; concentration possibly increased by
ritonavir.
Ciclosporin: may potentiate nephrotoxicity.
Cytotoxics: reduced excretion of methotrexate;
increased risk of bleeding with erlotinib.
Diuretics: increased risk of nephrotoxicity;
antagonism of diuretic effect; hyperkalaemia with
potassium-sparing diuretics.
Lithium: excretion decreased.
Pentoxifylline: increased risk of bleeding.
Tacrolimus: increased risk of nephrotoxicity.
Metabolism
Metabolised in the liver via cytochrome P450 2C9 to
several pharmacologically inactive metabolites (mainly
5'-hydroxy-tenoxicam).
Metabolites are excreted mainly in the urine; there is
some biliary excretion of glucuronide conjugates of the
metabolites.
Check Digit Verification of cas no
The CAS Registry Mumber 59804-37-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,9,8,0 and 4 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 59804-37:
(7*5)+(6*9)+(5*8)+(4*0)+(3*4)+(2*3)+(1*7)=154
154 % 10 = 4
So 59804-37-4 is a valid CAS Registry Number.
InChI:InChI=1/C13H11N3O4S2/c1-16-10(13(18)15-9-4-2-3-6-14-9)11(17)12-8(5-7-21-12)22(16,19)20/h2-7,17H,1H3,(H,14,15,18)
59804-37-4Relevant articles and documents
Preparation method of tenoxicam
-
, (2017/10/26)
The invention discloses a preparation method of tenoxicam and belongs to the technical field of medicine preparation. The preparation method comprises the following steps: using 3-chlorosulfonyl-2-thiophenecarboxylate, namely TNXK-0 as a raw material to synthesize 3-((N-(methoxycarbonyl) methyl) sulfonyl)-2-thiophenecarboxylate, namely TNXK-1; using the TNXK-1 as a raw material to synthesize 4-hydroxy-2H-thieno (2,3e)-1,2-thiazine-3-methyl formate-1,1-dioxide, namely TNXK-2; using the TNXK-2 as a raw material to synthesize 4-hydroxy-2-methyl-2H-thieno (2,3e)-1,2-thiazine-3-methyl formate-1,1-dioxide, namely TNXK-3; using the TNXK-3 and 2-aminopyridine as raw materials to synthesize the tenoxicam. The preparation method of the tenoxicam, disclosed by the invention, has the advantages of simple process, high yield and low cost; the purity of an obtained product is high.
Tenoxicam preparation method
-
, (2017/08/31)
The invention relates to a tenoxicam preparation method. Tenoxicam is prepared by taking 3-chlorosulfonylthiophene-2-dimethyl carbonate as an initial raw material, reacting 3-chlorosulfonylthiophene-2-dimethyl carbonate with 2-amino-N-pyridyl acetamide, performing cyclization in an alkaline condition, and performing methylation with dimethyl carbonate. The preparation route is shown as in the description. The preparation method has advantages that the raw materials are low in price and are available and the production cost is saved. In the meantime, final aminolysis is not required in the preparation method, the reaction is complete, and the yield is no less than 85%. The raw materials and product are not carbonized or decomposed, the side reaction is reduced, and the product is easy to be purified, so that the purity of the product can reach 99.98%. The preparation method is suitable for industrial production.
Analogues and Derivatives of Tenoxicam. 1. Synthesis and Antiinflammatory Activity of Analogues with Different Residues on the Ring Nitrogen and the Amide Nitrogen
Binder, Dieter,Hromatka, Otto,Geissler, Franz,Schmied, Karl,Noe, Christian R.,et al.
, p. 678 - 682 (2007/10/02)
The synthesis of tenoxicam, 4-hydroxy-2-methyl-N-2-pyridyl-2H-thieno-1,2-thiazine-3-carboxamide 1,1-dioxide (1e), and of the analogues with various residues on the ring nitrogen and the amide nitrogen is described.This new class of "oxicams" has pronounced antiinflammatory and analgesic properties.The very specific structure-activity relationship of isomeric and isosteric groups at the amide nitrogen has been evaluated.The substituent in position 2 also has a great influence on the pharmacological properties.Tenoxicam is presently underrgoing clinical trials.